Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Inhibition of Cdk Activity
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.
Related Experiment Video
Updated: Mar 27, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Obinutuzumab: the more the merrier?
1THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
Higher doses of obinutuzumab, an anti-CD20 monoclonal antibody, showed improved response rates in chronic lymphocytic leukemia (CLL) patients. However, increased dosage did not significantly impact progression-free survival in this phase 2 study.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Obinutuzumab is an anti-CD20 monoclonal antibody used in CLL treatment.
- Optimizing obinutuzumab dosage is crucial for treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of two different doses of obinutuzumab in previously untreated CLL patients.
- To compare the overall response rate (ORR) and progression-free survival (PFS) between standard and higher doses of obinutuzumab.
Main Methods:
- Randomized phase 2 study.
- 78 previously untreated CLL patients.
- 8 cycles of obinutuzumab at 1000 mg (standard) or 2000 mg (higher dose).
More Related Videos
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Main Results:
- Higher dose obinutuzumab resulted in a significantly higher ORR (67% vs 49%).
- No significant difference in progression-free survival (PFS) was observed between the two dose groups.
- Safety data was not detailed in the provided abstract.
Conclusions:
- Higher dose obinutuzumab may improve initial response rates in treatment-naive CLL.
- Current data does not support a PFS benefit with escalated obinutuzumab dosing.
- Further research is needed to determine the optimal dosing strategy for obinutuzumab in CLL.